LFB-190 / Leapfrog Bio - LARVOL DELTA

Leapfrog Bio Presents Novel Genetic Sensitizing Mutation Linked to BET Inhibitors and Clinical Development Plans for Lead Product Candidate at the AACR Special Conference in Cancer Research (GlobeNewswire) - "Leapfrog Bio...announced that Tomas Babak...will present evidence that Leapfrog Bio’s Precision PGx Platform discovered a clinically significant link between the EP300 gene and bromodomain and extra-terminal domain (BET) protein inhibitors. The presentation...will take place at the AACR Special Conference in Cancer Research...and will focus on the discovery, characterization and clinical development plan for Leapfrog Bio’s BET inhibitor LFB-190 to treat solid tumors with EP300 loss of function...After conducting hundreds of pharmacogenetic screens using its Precision PGx Platform, Leapfrog Bio discovered an interaction between BET protein inhibition and the EP300 gene loss of function (LOF) similar to PARP-BRCA1/HRD in significance....'We have filed IP around this discovery and are currently preparing for LFB-190’s entry into Phase 2 in lung, colon and bladder cancers in 2025.'"

Clinical • New P2 trial • Bladder Cancer • Colon Cancer • Oncology • Solid Tumor